About RxCelerate
RxCelerate is a leading drug discovery and development platform. We are driven by a mission to improve patients’ lives through scientific excellence and innovation.
We focus on solving complex scientific challenges based on first principles, working out our clients’ specific needs to get their potential drug to the clinic. Rather than fitting to existing models, we specialise in bespoke experimental design with data-rich endpoints, maximising the chances of clinical success while reducing long-term costs.
Our highly talented team of scientists bring expertise across the entire drug discovery pathway. By combining integrated teams with our unique technologies, we’ll design the right strategy to drive your asset through drug discovery, preclinical research and beyond.
Cutting-edge technologies
These include RxNfinity™ for rapid in silico screening, the Galaxy® platform for generating diverse ‘clinic-ready’ antibodies, and ProQuant® for precise bottom-up proteomics across diverse biological samples.
Comprehensive services
We cover the entire discovery and development spectrum, including in silico design and discovery, antibody discovery, synthetic and medicinal chemistry, in vitro services, preclinical services, and project management.
Bespoke and flexible experimental design
We de-risk assets through real-time data analysis and collaborative strategic thinking. Enabling informed, intelligent decisions for efficient, well-executed iterative experiments.
Our Mission
We believe in scientific excellence, based on first principles, that creates maximal value when paired with cost and operational efficiency. Every client project is unique and our bespoke design and approach is centered on de-risking the asset through real-time data analysis and collaborative strategic thinking, which allows for informed and intelligent decision making throughout the drug development process.
Our Impact In Numbers
Over the last ten years RxCelerate has contributed to…
25+
clinical candidates
14
drugs in the clinic
Who we work with…
75%
repeat business
1/3
of our client base are virtual
Our Background
RxCelerate is the realisation of a shared vision by its founders, David Grainger and Jill Reckless. With a partnership that spans almost 30 years, their journey began at Cambridge University, where they worked together under Professor Jim Metcalfe’s guidance. During this time, they noticed that the resources and infrastructure needed for innovative drug development were often out of reach for smaller, independent groups, leaving valuable ideas unexplored. In 2011, David’s experience at Index Ventures (later Medicxi) highlighted similar challenges faced by biotech startups. So, in April 2013, they founded RxCelerate to fill this gap, creating a platform covering every aspect of drug discovery and development. Today, the RxCelerate team has grown to over a hundred experts, all driven by the mission to democratise drug discovery and development, making it accessible to anyone with a promising idea.
The RxCelerate Group
RxCelerate, including sister companies, RxBiologics and The Cambridge Partnership, offers a complete solution for today’s complex R&D demands. Across small molecules and biologics, with expert scientific execution and back-office support, we keep your asset moving forward.
The RxBiologics Galaxy® Antibody Discovery Platform together with RxCelerate’s biology, in silico design, chemistry and programme management capabilities, enables us to deliver world-leading antibody drug discovery programmes.
The Cambridge Partnership is the only professional services company in the UK exclusively dedicated to supporting companies in the biotechnology industry. We specialise in providing a “one-stop-shop” for finance, company secretarial and admin services.
RxCelerate offers a unique business model catering to both small molecules and biologics. We work with you to drive your asset through drug discovery, preclinical research and beyond.
We do not follow the one-size-fits-all approach used by many other contract research organisations. Instead, we tailor our R&D services to meet the specific needs of each programme, bringing scientific insight, strategic thinking and flexibility to each collaboration. From rapid small molecule screening to designing bespoke assays and tailored in vivo models, we build solutions from first principles that align with specific scientific goals, timelines and investment milestones.